The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Tandem Meetings 2023 | The impact of gender on the outcomes of patients with myeloma undergoing autologous transplantation
Muzaffar Qazilbash, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the findings of a study investigating the impact of gender on survival outcomes in patients with multiple myeloma undergoing autologous transplantation. Overall, the study reported that there was no significant difference in progression-free survival (PFS) between males and females. However, a subset analysis found that females younger than 50 years old appeared to have a shorter PFS when compared to age-matched males. This result could be hypothesis-generating if reproduced in other datasets. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
